N THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

BOWEN et al.

SERIAL NO.:

10/502,080

FILED:

10/08/2004

FOR:

SOLENOPSIN A, B AND ANALOGS AS NOVEL

ANGIOGENESIS INHIBITORS

GROUP ART UNIT:

4133

EXAMINER:

KUDLA, Joseph S.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56(a), applicant encloses herewith a copy of Form PTO-1449 listing patent documents relevant to the background of the invention described and claimed in the above-identified application. Inclusion of a document on this list does not necessarily imply that that document is prior art. Copies of the listed documents are not enclosed.

Applicant respectfully requests that the Examiner consider the enclosed references in determining the patentability of the claimed invention. Applicant also requests that the Examiner return a copy of enclosed Form PTO-1449 with initials or other marks indicating that the references have been so considered. If any fee is due, please charge/credit deposit account no. 04-0838.

Respectfully submitted,

Coleman Sudol Sapone, P.C.

Hent D. Colleman

Reg. No. 32/559 714 Colorado Avenue

Bridgeport, Connecticut 06605-1601

(203)366-3560

Dated: (3, -07